Biotech · Private company · Portland, CA, US
Circumvent Pharmaceuticals, Inc.
Track this companyFree. Adds Circumvent Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards2
- Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a Therapeutic Agent for Treating CLN1 Batten DiseaseFiscal year 2026 · $1.2MNIH RePORTER 5R44NS120360-04 · fetched Nov 12, 2026
- Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten DiseaseFiscal year 2025 · $1.2MNIH RePORTER 2R44NS120360-03 · fetched Nov 12, 2026